National Institute of Allergy and Infectious Diseases awarded a 3-year $ 2.8 million grant to a partnership between BioAegis and TH Chan Harvard School of Public Health researchers. The grant will advance the study of pGSN replacement as a therapy for antibiotic-resistant pneumonia. The highly competitive R01 grant was responsive to a Request for Applications entitled: “Partnerships for the Development of Host-Targeted Therapeutics to Limit Antimicrobial Resistance.”

Read the full release NIH Grant Press Release June 9 2016


BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 30, 2015) BioAegis Therapeutics announces that it has sold a combination of net operating losses and R&D Credits totaling $544,000. The company’s application to this State of New Jersey’s Technology Business Tax Credit Transfer Program was previously accepted in June.


Company Develops Temperature-Stable Lyophilized Protein

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 30, 2015) BioAegis Therapeutics announces that it has successfully completed development of a lyophilized form of plasma gelsolin.
Lyophilization is the process of converting the bulk drug substance into a freeze-dried
form that can be stored in vials at room temperature. This eliminates the necessity of cold-chain storage, facilitating use in the clinic and minimizing storage and shipping costs.


Patents Granted for Renal Failure in Japan and Inflammation in Korea

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – September, 2015) BioAegis Therapeutics announced today patents were recently granted covering plasma gelsolin uses for renal failure in Japan and inflammation in Korea. Further applications in jurisdictions in Asia are also pending.


NIAID Anticipates Funding Host-Based Approaches to Antimicrobial Resistance

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – August 15, 2015) BioAegis Therapeutics announces that it has met with representatives from The National Institute of Allergy and Infectious Diseases (NIAID) and The Biomedical Advanced Research Development Agency (BARDA) to discuss plasma gelsolin’s role in in combatting antibiotic resistance. The meeting was prompted by a recent National Action Plan sponsored by the White House to slow the emergence of resistant bacteria and prevent the spread of resistant infections. Plasma gelsolin offers a unique approach to solving this enormous threat to public health by using a host-based approach–empowering the body’s immune system to combat both bacterial and viral threats, especially where current therapies fail.